Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression

Lina Song,1,2 Wei Zhang,3 Hong Chen,4 Xizhi Zhang,1 Haoan Wu,1 Ming Ma,1 Zhongqiu Wang,2 Ning Gu,1 Yu Zhang1 1State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering & Collaborative Innovation Centre o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Song L, Zhang W, Chen H, Zhang X, Wu H, Ma M, Wang Z, Gu N, Zhang Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	magnetic nanoprobes rituximab malignant lymphoma cells CD20 apoptosis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ccbd5fa4ab0f44f9b21c831e86952397
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ccbd5fa4ab0f44f9b21c831e86952397
record_format	dspace
spelling	oai:doaj.org-article:ccbd5fa4ab0f44f9b21c831e869523972021-12-02T02:20:20ZApoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression1178-2013https://doaj.org/article/ccbd5fa4ab0f44f9b21c831e869523972019-02-01T00:00:00Zhttps://www.dovepress.com/apoptosis-promoting-effect-of-rituximab-conjugated-magnetic-nanoprobes-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Lina Song,1,2 Wei Zhang,3 Hong Chen,4 Xizhi Zhang,1 Haoan Wu,1 Ming Ma,1 Zhongqiu Wang,2 Ning Gu,1 Yu Zhang1 1State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering & Collaborative Innovation Centre of Suzhou Nano Science and Technology, Southeast University, Nanjing 210096, People’s Republic of China; 2Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, People’s Republic of China; 3The Jiangsu Province Research Institute for Clinical Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210009, People’s Republic of China; 4Department of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, People’s Republic of China Background: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands of lives. However, many people cannot benefit from rituximab treatment because of drug resistance or side effects.Methods: In this study, a 13-nm rituximab-conjugated magnetic nanoparticle was developed as a therapeutic nanoprobe targeting CD20 overexpressing malignant lymphoma cells to enhance the treatment effects of rituximab. The magnetic cores (2,3-dimercaptosuccinicacid modified Fe3O4 nanoparticles, Fe3O4@DMSA) of the nanoprobes with an average diameter of 6.5 nm were synthesized using a co-precipitation method. Rituximab was then conjugated on the surface of Fe3O4@DMSA using a cross-linking agent (carbodiimide/N-hydroxysulfosuccinimide sodium salt). Based on theoretical calculations, approximately one antibody was coupled with one nanoparticle, excluding the multivalent antibody effect.Results: Cell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe3O4@DMSA@Ab nanoprobes have specific binding affinity for CD20-positive cells. Compared to rituximab and Fe3O4@DMSA, Fe3O4@DMSA@Ab nanoprobes significantly reduced cell viability and promoted Raji cell apoptosis. Initiating events of apoptosis, including increased intracellular calcium and reactive oxygen species, were observed in nanoprobe-treated Raji cells. Nanoprobe-treated Raji cells also showed the most drastic decrease in mitochondrial membrane potential and Bcl-2 expression, compared to rituximab and Fe3O4@DMSA-treated Raji cells.Conclusion: These results indicate that Fe3O4@DMSA@Ab nanoprobes have the potential to serve as MRI tracers and therapeutic agents for CD20-positive cells. Keywords: CD20-targeted nanoprobes, calcium, reactive oxygen species, ROS, mitochondrial membrane potential, MMP, cell apoptosis  Song LZhang WChen HZhang XWu HMa MWang ZGu NZhang YDove Medical Pressarticlemagnetic nanoprobesrituximabmalignant lymphoma cellsCD20apoptosisMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 921-936 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	magnetic nanoprobes rituximab malignant lymphoma cells CD20 apoptosis Medicine (General) R5-920
spellingShingle	magnetic nanoprobes rituximab malignant lymphoma cells CD20 apoptosis Medicine (General) R5-920 Song L Zhang W Chen H Zhang X Wu H Ma M Wang Z Gu N Zhang Y Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
description	Lina Song,1,2 Wei Zhang,3 Hong Chen,4 Xizhi Zhang,1 Haoan Wu,1 Ming Ma,1 Zhongqiu Wang,2 Ning Gu,1 Yu Zhang1 1State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering & Collaborative Innovation Centre of Suzhou Nano Science and Technology, Southeast University, Nanjing 210096, People’s Republic of China; 2Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, People’s Republic of China; 3The Jiangsu Province Research Institute for Clinical Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210009, People’s Republic of China; 4Department of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, People’s Republic of China Background: Cancer targeting nanoprobes with precisely designed physicochemical properties may show enhanced pharmacological targeting and therapeutic efficacy. As a widely used commercialized antibody, rituximab has been in clinical use for three decades and has lengthened or even saved thousands of lives. However, many people cannot benefit from rituximab treatment because of drug resistance or side effects.Methods: In this study, a 13-nm rituximab-conjugated magnetic nanoparticle was developed as a therapeutic nanoprobe targeting CD20 overexpressing malignant lymphoma cells to enhance the treatment effects of rituximab. The magnetic cores (2,3-dimercaptosuccinicacid modified Fe3O4 nanoparticles, Fe3O4@DMSA) of the nanoprobes with an average diameter of 6.5 nm were synthesized using a co-precipitation method. Rituximab was then conjugated on the surface of Fe3O4@DMSA using a cross-linking agent (carbodiimide/N-hydroxysulfosuccinimide sodium salt). Based on theoretical calculations, approximately one antibody was coupled with one nanoparticle, excluding the multivalent antibody effect.Results: Cell targeting experiments and magnetic resonance (MR) signal and T2 measurements showed that the Fe3O4@DMSA@Ab nanoprobes have specific binding affinity for CD20-positive cells. Compared to rituximab and Fe3O4@DMSA, Fe3O4@DMSA@Ab nanoprobes significantly reduced cell viability and promoted Raji cell apoptosis. Initiating events of apoptosis, including increased intracellular calcium and reactive oxygen species, were observed in nanoprobe-treated Raji cells. Nanoprobe-treated Raji cells also showed the most drastic decrease in mitochondrial membrane potential and Bcl-2 expression, compared to rituximab and Fe3O4@DMSA-treated Raji cells.Conclusion: These results indicate that Fe3O4@DMSA@Ab nanoprobes have the potential to serve as MRI tracers and therapeutic agents for CD20-positive cells. Keywords: CD20-targeted nanoprobes, calcium, reactive oxygen species, ROS, mitochondrial membrane potential, MMP, cell apoptosis
format	article
author	Song L Zhang W Chen H Zhang X Wu H Ma M Wang Z Gu N Zhang Y
author_facet	Song L Zhang W Chen H Zhang X Wu H Ma M Wang Z Gu N Zhang Y
author_sort	Song L
title	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
title_short	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
title_full	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
title_fullStr	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
title_full_unstemmed	Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
title_sort	apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with cd20 overexpression
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/ccbd5fa4ab0f44f9b21c831e86952397
work_keys_str_mv	AT songl apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT zhangw apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT chenh apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT zhangx apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT wuh apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT mam apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT wangz apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT gun apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression AT zhangy apoptosispromotingeffectofrituximabconjugatedmagneticnanoprobesonmalignantlymphomacellswithcd20overexpression
_version_	1718402556289351680

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression

Ejemplares similares